Polymer membranes for continuous analyte sensors
Devices and methods are described for providing continuous measurement of an analyte concentration. In some embodiments, the device has a sensing mechanism and a sensing membrane that includes at least one surface-active group-containing polymer and that is located over the sensing mechanism. The sensing membrane may have a bioprotective layer configured to substantially block the effect and/or influence of non-constant noise-causing species.
1. A device for continuous in vivo measurement of a glucose concentration, the device comprising:
an implantable sensor configured to continuously measure a signal indicative of a glucose concentration in a host, wherein the implantable sensor comprises an electroactive surface; and
a membrane located over the implantable sensor, wherein the membrane comprises a first domain comprising an enzyme configured to react with glucose to produce a measured species configured to be oxidized at the implantable sensor, wherein the membrane comprises a second domain comprising a blend comprising:
a polymer comprising a hydrophilic segment, and
a polyurethane comprising a plurality of repeating hard segments and repeating soft segments, wherein a soft segment of the plurality of repeating soft segments has a molecular weight from about 200 Daltons to about 50,000 Daltons, wherein a hard segment of the plurality of repeating hard segments has a molecular weight from about 160 Daltons to about 10,000 Daltons, wherein the blend of the polymer and the polyurethane comprises both hydrophilic and hydrophobic regions; and
sensor electronics operably connected to the implantable sensor, wherein the sensor electronics are configured to measure a current flow produced by the sensor to generate sensor data indicative of glucose concentration.
2. The device of claim 1 , wherein the polyurethane is a polyurethaneurea.
3. The device of claim 1 , wherein the hydrophilic segment comprises acrylate.
4. The device of claim 1 , wherein the membrane comprises a third domain configured to reduce permeation therethrough of an interfering species.
5. The device of claim 1 , wherein the third domain is located between the implantable sensor and the first domain.
6. The device of claim 1 , wherein the third domain comprises a polymer comprising ionic components.
7. The device of claim 1 , wherein the third domain is configured to limit diffusion of interfering species with a molecular weight greater than a molecular weight of hydrogen peroxide.
8. The device of claim 1 , wherein the polyurethane is polyurethaneurea, wherein the hydrophilic segment comprises acrylate.
9. The device of claim 1 , wherein the polyurethane is polyurethaneurea, wherein the hydrophilic segment comprises acrylate, wherein the membrane comprises a third domain configured to reduce permeation therethrough of an interfering species.
10. The device of claim 1 , wherein the polyurethane is polyurethaneurea, wherein the hydrophilic segment comprises acrylate, wherein the membrane comprises a third domain configured to reduce permeation therethrough of an interfering species, wherein the third domain is located between the implantable sensor and the first domain.
11. The device of claim 1 , wherein the hydrophilic segment is selected from the group consisting of: polyvinyl acetate, poly(ethylene glycol), polyacrylamide, acetates, polyethylene oxide, polyvinylpyrrolidone, and poly ethyl acrylate.
12. The device of claim 1 , wherein the polyurethane comprises silicone.
13. The device of claim 12 , wherein the polyurethane comprises from about 10% to about 50% silicone by weight.
14. The device of claim 13 , wherein the polyurethane comprises from about 20% to about 40% silicone by weight.
15. The device of claim 1 , wherein the polyurethane is polyurethaneurea, wherein the hydrophilic segment comprises acrylate, wherein the polyurethane comprises silicone.
16. The device of claim 1 , wherein the polymer comprising the hydrophilic segment comprises from about 5% to about 50% by weight of the blend.
17. The device of claim 1 , wherein the polyurethane is polyurethaneurea, wherein the hydrophilic segment comprises acrylate, wherein the polymer comprising the hydrophilic segment comprises from about 5% to about 50% by weight of the blend.
18. The device of claim 1 , wherein the device is configured to have a sensor session from 5 to 10 days.
19. The device of claim 1 , wherein the device is configured to provide, at glucose concentrations of from about 40 mg/dL to about 400 mg/dL, a level of accuracy corresponding to a mean absolute relative difference of no more than 10% over a sensor session of from 6 to 10 days, wherein one or more reference measurements related to calculation of the mean absolute relative difference are determined by analysis of blood.
20. A device for continuous in vivo measurement of a glucose concentration, the device comprising:
an implantable sensor configured to continuously measure a signal indicative of a glucose concentration in a host, wherein the implantable sensor comprises an electroactive surface; and
a membrane located over the implantable sensor, wherein the membrane comprises a first domain comprising an enzyme configured to react with glucose to produce a measured species configured to be oxidized at the sensor, wherein the membrane comprises a second domain comprising a blend comprising:
a polymer comprising a hydrophilic segment, wherein the hydrophilic segment comprises acrylate, wherein the polymer comprising the hydrophilic segment comprises from about 5% to about 50% by weight of the blend, and
a polyurethane comprising a plurality of repeating hard segments and repeating soft segments, wherein a soft segment of the plurality of repeating soft segments has a molecular weight from about 200 Daltons to about 50,000 Daltons, wherein a hard segment of the plurality of repeating hard segments has a molecular weight from about 160 Daltons to about 10,000 Daltons, wherein the polyurethane comprises silicone, wherein the polyurethane is a polyurethaneurea, wherein the blend of the polymer and the polyurethane comprises both hydrophilic and hydrophobic regions; and
sensor electronics operably connected to the sensor, wherein the sensor electronics are configured to measure a current flow produced by the sensor to generate sensor data indicative of glucose concentration;
wherein the device is configured to have a sensor session from 5 to 10 days.
21. The device of claim 1 , wherein the second domain is configured to control diffusion therethrough of glucose and oxygen.
22. The device of claim 20 , wherein the second domain is configured to control diffusion therethrough of glucose and oxygen.
23. A device for in vivo measurement of a glucose concentration, the device comprising:
an implantable sensor configured to measure a signal indicative of a glucose concentration in a host;
a membrane located over the implantable sensor, wherein the membrane comprises
a polycarbonate-urethane polymer comprising a plurality of repeating hard segments and repeating soft segments, wherein a soft segment of the plurality of repeating soft segments has a molecular weight from 200 Daltons to 50,000 Daltons, wherein a hard segment of the plurality of repeating hard segments has a molecular weight from 160 Daltons to 10,000 Daltons, wherein the membrane comprises both hydrophilic and hydrophobic regions; and
sensor electronics operably connected to the sensor, wherein the sensor electronics are configured to measure a signal produced by the sensor to generate sensor data indicative of glucose concentration.
24. The device of claim 23 , wherein the hydrophilic regions are configured to permit glucose to diffuse therethrough.
25. The device of claim 24 , wherein the hydrophilic regions comprise channels through which glucose molecules are to pass through during a sensor session.
26. The device of claim 23 , wherein the membrane comprises an enzyme that is immobilized.
27. The device of claim 23 , wherein the membrane has a thickness from 1 micron to 100 microns.
28. The device of claim 27 , wherein the membrane has a thickness from 1 micron to 40 microns.
29. The device of claim 23 , wherein the membrane is configured to create thermodynamically-driven separation between hydrophilic portions and hydrophobic portions during a period after sensor insertion.
30. The device of claim 23 , wherein the membrane comprises a bioprotective or biointerface domain, wherein the bioprotective or biointerface domain comprises the polycarbonate-urethane polymer.
31. The device of claim 23 , wherein the membrane comprises a resistance domain, wherein the resistance domain comprises the polycarbonate-urethane polymer.
32. The device of claim 23 , wherein the membrane comprises an enzyme domain, wherein the enzyme domain comprises the polycarbonate-urethane polymer.
33. The device of claim 23 , wherein the membrane comprises an electrode domain, wherein the enzyme domain comprises the polycarbonate-urethane polymer.
34. The device of claim 23 , wherein the membrane comprises an interference domain, wherein the enzyme domain comprises the polycarbonate-urethane polymer.
35. The device of claim 23 , wherein the polycarbonate-urethane polymer does not comprise silicone.
36. The device of claim 23 , wherein the polycarbonate-urethane polymer does not comprise a hydrophilic segment.
37. The device of claim 23 , wherein the device is configured to produce an equivalent glucose signal of no more than about 30 mg/dL in a test concentration about 3 mg/dL of acetaminophen.
38. The device of claim 23 , wherein the device is configured to produce an equivalent glucose signal of no more than about 17 mg/dL in a test concentration of about 6 mg/dL of ascorbic acid.
39. The device of claim 23 , wherein the device is configured to produce an equivalent glucose signal of no more than about 25 mg/dL in a test concentration of about 6 mg/dL of uric acid.
40. The device of claim 39 , wherein the substantially fixed in vivo to in vitro sensitivity ratio is from 1 to 1.5 to 1 to 10.
41. The device of claim 39 , wherein the substantially fixed in vivo to in vitro sensitivity ratio is from 1 to 0.1 and about 1 to 0.7.
42. The device of claim 39 , wherein the in vivo to in vitro sensitivity ratio is substantially fixed across a fixed population of sensors manufactured.
43. The device of claim 39 , wherein the polycarbonate-urethane polymer comprises a urea segment.
44. The device of claim 23 , wherein the membrane is configured to provide the sensor a substantially fixed in vivo to in vitro sensitivity ratio.